Company profile
Rein Therapeutics Inc.
NASDAQ: RNTX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
36DFH 26DQ 49GM —SS 41
v0.1 · 55/100 weight · provisional
↑ disclosure history, balance-sheet leverage · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$49.9M
Employees
10
as of 2026-08-20
Market cap
$22.1M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$49.9M-$49.9M2025
Operating income-$50.6M-$50.6M2025
Total assets$24.2M$24.2M2025
Liabilities$7.2M$7.2M2025
Equity$16.9M$16.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rein Therapeutics Inc.’s revenue?
Rein Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Resverlogix Corp.——EOM Pharmaceuticals Holdings, Inc.——Barinthus Biotherapeutics plc39DOcumetics Technology Corp.——KALA BIO, Inc.30DTvardi Therapeutics, Inc.35DNeighbors
Travis →Key facts
CEOJames Brian Windsor
SectorHealthcare
IndustryBiotechnology
HeadquartersAustin, TX
ExchangeNASDAQ: RNTX
Employees10
IPO date2017-06-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.